PuF, An Antimetastatic and Developmental Signaling Protein, Interacts with the Alzheimer’s Amyloid-β Precursor Protein via a Tissue-Specific Proximal Regulatory Element (PRE) by Lahiri, Debomoy K et al.
 
PuF, An Antimetastatic and Developmental Signaling Protein,
Interacts with the Alzheimer’s Amyloid-β Precursor Protein via a
Tissue-Specific Proximal Regulatory Element (PRE)
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Lahiri, Debomoy K., Bryan Maloney, Jack T. Rogers, and Yuan-
Wen Ge. 2013. PuF, an antimetastatic and developmental
signaling protein, interacts with the Alzheimer’s amyloid-β
precursor protein via a tissue-specific proximal regulatory
element (PRE). BMC Genomics 14:68.
Published Version doi:10.1186/1471-2164-14-68
Accessed February 19, 2015 12:01:43 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10622927
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH ARTICLE Open Access
PuF, an antimetastatic and developmental
signaling protein, interacts with the Alzheimer’s
amyloid-β precursor protein via a tissue-specific
proximal regulatory element (PRE)
Debomoy K Lahiri
1,2,4*, Bryan Maloney
1, Jack T Rogers
3 and Yuan-Wen Ge
1
Abstract
Background: Alzheimer’s disease (AD) is intimately tied to amyloid-β (Aβ) peptide. Extraneuronal brain plaques
consisting primarily of Aβ aggregates are a hallmark of AD. Intraneuronal Aβ subunits are strongly implicated in
disease progression. Protein sequence mutations of the Aβ precursor protein (APP) account for a small proportion
of AD cases, suggesting that regulation of the associated gene (APP) may play a more important role in AD
etiology. The APP promoter possesses a novel 30 nucleotide sequence, or “proximal regulatory element” (PRE), at
−76/−47, from the +1 transcription start site that confers cell type specificity. This PRE contains sequences that
make it vulnerable to epigenetic modification and may present a viable target for drug studies. We examined
PRE-nuclear protein interaction by gel electrophoretic mobility shift assay (EMSA) and PRE mutant EMSA. This was
followed by functional studies of PRE mutant/reporter gene fusion clones.
Results: EMSA probed with the PRE showed DNA-protein interaction in multiple nuclear extracts and in human
brain tissue nuclear extract in a tissue-type specific manner. We identified transcription factors that are likely to bind
the PRE, using competition gel shift and gel supershift: Activator protein 2 (AP2), nm23 nucleoside diphosphate
kinase/metastatic inhibitory protein (PuF), and specificity protein 1 (SP1). These sites crossed a known single
nucleotide polymorphism (SNP). EMSA with PRE mutants and promoter/reporter clone transfection analysis further
implicated PuF in cells and extracts. Functional assays of mutant/reporter clone transfections were evaluated by
ELISA of reporter protein levels. EMSA and ELISA results correlated by meta-analysis.
Conclusions: We propose that PuF may regulate the APP gene promoter and that AD risk may be increased by
interference with PuF regulation at the PRE. PuF is targeted by calcium/calmodulin-dependent protein kinase II
inhibitor 1, which also interacts with the integrins. These proteins are connected to vital cellular and neurological
functions. In addition, the transcription factor PuF is a known inhibitor of metastasis and regulates cell growth
during development. Given that APP is a known cell adhesion protein and ferroxidase, this suggests biochemical
links among cell signaling, the cell cycle, iron metabolism in cancer, and AD in the context of overall aging.
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A diagnostic feature of Alzheimer’s disease (AD) is ag-
gregation of toxic amyloid β peptide (Aβ) into extracel-
lular plaques, suspected of causing or contributing to
disease progression [1,2]. In addition, intracellular Aβ
has been implicated as having a pathological role in AD
and Down syndrome [3], and Aβ may function as a tran-
scription factor (TF) [4,5]. Aβ is cleaved from a larger
precursor protein (APP) by a process involving two secre-
tase enzymes, β-secretase and γ-secretase [2]. Hyperpho-
sphorylated τ protein and α-synuclein also have a likely
role in AD etiology [6-8], and apolipoprotein E (APOE)i s
linked to a large proportion of cases of AD both by genetic
[9,10] and cholesterol-related functional studies [11]. We
hypothesize that unusually high production of Aβ signifi-
cantly contributes to AD, and this aberrant Aβ production
can result from unusually high APP gene (APP) expres-
sion, particularly in a tissue and cell-type specific manner.
Several groups have studied the 5
0-flanking region of
the APP gene, including its promoter [12-16]. Serial de-
letion analysis has shown that the APP promoter [14,17]
and 5
0-UTR [18] contain several regulatory elements that
are likely to modulate transcriptional activity. In addition
to proximal regulatory regions, two upstream sequences
have been identified that regulate the gene’s expression
[14], including one that has been shown to generally stimu-
late APP production [19]. The APP promoter is regulated
by a variety of factors. It can be stimulated by nerve growth
factor, fibroblast growth factor, and interleukin-l [20,21],
and copper depletion downregulates its activity [22]. A link
between APP gene regulation and pathologies such as AD
has been shown, for example, by characterization of two
APP promoter polymorphisms associated with the patho-
genesis of some forms of AD [23]. The more upstream of
these two polymorphic sites may function as a target site
for Aβ acting as a transcription factor [4,5].
Our group has examined regulatory regions of import-
ant AD-associated genes, including APOE [24,25] and
microtubule-associated protein τ (MAPT) [26]. We have
also previously characterized a deletion series of the APP
promoter in eight different cell lines from five different
tissue types in a chloramphenicol acetyltransferase (CAT)
reporter construct [27]. We discovered that a novel 30 nu-
cleotide (nt) sequence of −76 to −47 from the +1 tran-
scription start site (TSS) had differential effect depending
upon cell line. In human kidney epithelial cells, deletion of
this element resulted in 50-fold reduction of CAT reporter
gene activity. In human SK-N-SH neuroblastoma (NB)
cells, deletion resulted in a 3 to 4-fold gain of reporter
gene activity, the greatest NB cell expression for all clones
of the deletion series. We thus termed this region the
“proximal regulatory element” (PRE) of the APP gene. We
examined the nature of DNA-protein interaction with this
DNA fragment by gel electrophoretic mobility shift assay
(EMSA or gel shift). Notably, use of the PRE as a probe in
EMSA showed evidence of DNA-protein interaction with
this sequence in multiple cell line nuclear extracts and in
mouse brain tissue nuclear extract [27]. However, the spe-
cific nature of nuclear proteins that interact with the PRE
in different cell types was not determined at that time.
We continue our work on the PRE by exploring specific
DNA-protein interactions in EMSA, competition EMSA,
and antibody-supershift EMSA. Functional effects were
measured by creation of a library of mutant PRE sequences
w i t h i nap r e v i o u s l yc o n s t r u c t e d[ 1 7 ]APP-CAT fusion clone.
While we had previously shown that the PRE interacts with
nuclear proteins in a tissue-type specific manner, we herein
identified TFs that were likely bind to the PRE, specifically
activator protein 2 (AP2), nm23 nucleoside diphosphate
kinase/metastatic inhibitory protein (PuF), and specificity
protein 1 (SP1). We also characterized quantitative and
qualitative effects of mutating the PRE vs. DNA-protein
interaction in EMSA vs. both NB and rat neuronal pheo-
chromocytoma (PC12) cells and cell nuclear extracts. Func-
tional assays of PRE mutation effects were performed by
transiently transfecting the mutant-CATclones into human
neuroblastoma and rat neuronal pheochromocytoma cell
cultures. We discovered specific, significant mutation-
dependent function differences. We compared the EMSA
results to effects of the same mutations in functional
mutant-CAT clone transfection assays. Altering the PRE’s
ability to bind TF corresponded to functional changes in
promoter activity in a cell line-specific manner.
We determined that PuF and SP1 are candidates for
regulation of the APP gene through the PRE. PuF’s better-
known function is as an inhibitor of metastasis [28]. SP1 ac-
tivity in APP regulation has already been well demonstrated
[29-33]. SP1 sites have been located in both the promoter
[13,32,34] and 5
0-UTR portions of the APP 5
0-flanking re-
gion [35,36]. Our data led us to propose that SP1 and PuF
act antagonistically through the PRE, with SP1 stimulating
and PuF repressing APP transcription. These two TF sites
can be subject to natural variation in the human genome,
as they cross a known single nucleotide polymorphism
(SNP) [37]. The PRE sequence contains sites for DNA
methylation and oxidation, suggesting the site may be vul-
nerable to environmentally-mediated epigenetic modifica-
tion. Should such interference with PuF regulation of APP
increase risk of AD, it would be another similarity between
etiology of sporadic/idiopathic neuropsychiatric disorders
and oncogenesis, extending our previous work in develop-
ing the latent early-life associated regulation (LEARn)
model [38,39] of idiopathic neuropsychiatric disorders.
Results
Putative transcription factor sites within the PRE
The PRE with an additional 10nt flanking sequence at ei-
ther end was used with TESS [40] and MatInspector [41]
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dicted sites to mammal TF matrices and eliminating
redundant sites resulted in predicted affinities with sev-
eral transcription factors (Table 1), including AP2,
GATA binding proteins 1 (GATA1) and 2 (GATA2), two
GC boxes, paired box gene 4-a (Pax4a), PuF, Epstein-
Barr virus transcription factor R (R), SP1, and transcrip-
tion elongation regulator 1 (mammal homologue to zeste,
TCERG1). Truncated upstream stimulatory factor (USF)1
and USF2 sites were also found at the 3
0-end of the PRE.
The GC box is associated with the binding of several tran-
scription factors, including SP1, basic transcription elem-
ent binding protein (BTEB)1, BTEB2, and msh homeobox
1( M s x 1 ) .
DNA-protein interaction of the PRE by EMSA varies
among tissue types and cell line conditions
To investigate cell type specificity of PRE-protein inter-
actions, we used the PRE fragment in EMSA with nu-
clear extracts from PC12 and human cervical epithelial
(HeLa), SK-N-BE neuroblastoma (NB), and histiocytic
lymphoma (U937) cells (Figure 1A–C) and with nuclear
extracts from human tissues (Figure 1D). PC12 extracts
(Figure 1A) were obtained from both normal and hyp-
oxic cells (lanes 1–2). U937 extracts (Figure 1A) included
nuclei from untreated cells and from cells treated with
interferon (IFN)-γ, 12-O-tetradecanoylphorbol-13-acetate
(TPA), or TPA + IFN-γ (lanes 3–7). In addition, to test
specificity of PRE binding with untreated U937 extracts,
we also competed the PRE/U937 EMSA against 200x
molar excess unlabeled PRE fragment (lane 5). Nuclear ex-
tract EMSA showed definite interaction between the PRE
and both PC12 and U937 extracts. This interaction was
competed away with excess PRE in U937 extracts. DNA-
protein interactions could be altered by specific treatment
of cells from which extracts were taken. Hypoxia greatly
reduced the observed interaction in PC12 extracts (lane
2). Treatment with the cytokine IFN-γ may have slightly
increased interaction in U937 extracts (lane 4), but TPA
treatment seems to have produced a stronger result (lane
6). Combined TPA+IFN-γ treatment (lane 7) reduced
DNA-protein interaction levels, suggesting that more than
one pathway may be involved in interaction with the PRE
and that these interactions may compete with each other.
To narrow down candidate transcription factors pre-
dicted by TESS we conducted EMSA with 200x molar
excess of unlabeled oligomer pairs known to bind the
transcription factors activator protein 1 (AP1), AP2, and
SP1, respectively. In addition, to demonstrate that the
truncated USF1 site at the 3
0-end of the PRE is not ac-
tive, we competed against an unlabeled commercial
oligomer pair known to bind USF1 (Figure 1B, C). Two
assays were carried out under the same conditions, one
each with nuclear extracts from NB (Figure 1B) and
HeLa (Figure 1C) cells, respectively. In NB extracts,
competition against AP1, SP1, and USF1 binding oligo-
mer pairs (lanes 3, 5, 6) showed no difference with the
uncompeted lane sample (lane 1). Competition with un-
labeled PRE eliminated DNA-protein interactions (lane
2), while competition with AP2-binding oligomer pair
reduced but did not eliminate interaction, suggesting
that PRE interaction in neuronal cells may operate
through more than one pathway or at least with more
than one potential transcription factor.
Competition EMSA in HeLa extracts was in TPA-
treated extracts (Figure 1C, lanes 2–6). Comparing un-
treated HeLa nuclear extracts with TPA-treated extracts
revealed that TPA induction changed DNA-protein inter-
actions with the PRE (Figure 1C, lanes 1–2). Competition
with the PRE nearly eliminated DNA-protein interaction
(lane 3). Competition with oligomer pairs that bind AP1
Table 1 Predicted TF sites in the PRE
Factor Sequence within PRE
a MW
(kDa)
c
AP2 GGGGTGGGCCG 32, 40, 47,
48, 49, 50,
51, 52
BTEB1
e GAGCGG
GGCCGG
BTEB2
e GAGCGG 25
GGCCGG
GATA1 GGGTGGGC 43, 51
CCGGATCAGc
GATA2 CCGGATCAGc 50
Msx1
e GAGCGG 31
GGCCGG
Pax4α GGGGTGGGCCGG 38
PuF GGGTGGG 17
R GTGCCGAGCGGGGTGGGC 67
SP1
b,e GGGTGG 81, 95,
105
TGGGCCGGATCAGctg
GAGCGG
GGCCGG
TCERG1CGAGTG 122, 124
d
CGAGCG
USF1 GGATCAGctgactc 34, 43, 55
USF2 GGATCAGctgactc 37, 44
aAll sequences presented in the same orientation as the PRE. Partial sites are
also listed, with bases that extend past the PRE indicated by dashes.
bTwo distinct SP1 sites were identified in the wildtype PRE sequence in
addition to the GC Box.
cUnless otherwise indicated, MW are for isoforms listed in the TransFac
database [42].
dMW is calculated from predicted genomic amino acid sequence.
eOne of several potential GC Box-binding factors.
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Radiolabeled PRE was incubated with PC12 or U937 nuclear extracts. PC12 extracts were either normal (lane 1) or from cells subject to hypoxia
(lane 2). U937 extracts were either normal (lanes 3, 6) or from INF-γ induced (lane 4), TPA-induced (lane 6), or TPA + INF-γ induced cells (lane 7).
In addition, one sample of normal U937 extract was incubated both with labeled and 200x molar excess of unlabeled PRE (lane 5). Arrows
indicate major DNA-protein interactions. B, C. The PRE fragment from plasmid pβXbB was radiolabeled and incubated in NB or HeLa cell nuclear
extracts with or without 200x molar excess competition against oligomers known to bind specific transcription factors. DNA-protein interactions
are indicated with arrows. B. NB cell nuclear extracts. No competition (lane 1), competition vs. unlabeled PRE (lane 2), competition vs. unlabeled
oligomers that bind AP1 (lane 3), AP2 (lane 4), SP1 (lane 5), or USF1 (lane 6). C. HeLa (lane 1) or TPA-stimulated HeLa (lanes 2–6) nuclear extracts.
Reactions were subjected to no competition (lanes 1–2) competition vs. 200x molar excess of unlabeled PRE fragment (lane 3), AP1-binding
oligomer (lane 4), AP2-binding oligomer, or USF-binding oligomer (lane 5). D. EMSA of the PRE in four human tissue nuclear extracts. The DNA
fragment corresponding to the PRE (−76/-47) was purified from plasmid pβXbB, radiolabeled, and incubated in nuclear extracts from human lung
(lane 1), liver (lane 2), heart (lane 3), or brain (lane 4). DNA-protein interaction band is indicated by arrow. Unbound probe ran at the bottom of
the gel (not shown).
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interaction. Competition with the USFl-binding oligomer
pairs showed little difference to uncompeted TPA-treated
extracts (lane 6). These results indicate that the PRE may
interact with AP2, at the very least, but AP2 is neither the
sole interaction partner for the PRE in neuronal cells nor
under phorbol ester induction.
To directly explore tissue specificity of PRE interaction
with factors present specifically in whole-tissue human
organs in addition to cell cultures, we also carried out
EMSA of the PRE fragment in human brain, heart, liver,
and lung nuclear extracts. Two of the four extracts
tested formed DNA-protein complexes with the PRE,
specifically lung and brain extracts (Figure 1D lanes 1,
4). This suggests that the PRE is likely to have tissue-
specific function in vivo, in addition to what may be sug-
gested by cell culture results, and that the brain is at
least one center of such affinity.
DNA-protein interactions in NB nuclear extracts is TF
specific by gel supershift EMSA
For further information on specific nuclear factors that
would interact with the PRE, we performed supershift
EMSA with radiolabeled PRE oligomer pairs in NB nu-
clear extracts (Figure 2). Extracts were either untreated
or co-incubated with antibodies against nuclear factors
AP1, AP2, PuF, SP1, or combined AP2 + PuF. As
negative controls, we incubated NB extracts with la-
beled PRE oligomer pairs and antibodies against USF1
or USF2.
Incubation of PRE oligomers with NB extracts was not
altered by co-incubation with anti-AP1 (lanes 1–2), pri-
marily consisting of a single band. As predicted, anti-
AP2 and anti-PuF each altered binding of the PRE with
NB extracts (lanes 3–4). In addition to reducing the
major DNA-protein interaction of un-competed PRE
(band III), new DNA-protein interactions (bands V and
VI) became visible when anti-AP2 was co-incubated.
Co-incubation with anti-PuF produced a similar pattern
to anti-AP2, with an additional band (IV). Of particular
interest is that co-incubation with both antibodies
reduced DNA-protein interaction more than did incuba-
tion with either antibody alone, and completely elimi-
nated the interaction at band III (lane 5).
Co-incubation with anti-SP1 produced a more classic
“shift” response (lane 6, band I). Co-incubation with
anti-USF1 (lane 7) did not result in any changes. Co-
incubation with anti-USF2, on the other hand, produced
a response similar to that found with anti-AP2 or anti-
PuF. In addition, band II appears, but this band may also
be already present but masked by the breadth of band
III in untreated reactions. Close examination of lane I
indicates that the interaction at band VI may also be
present in untreated reactions. Bands IV and V, on the
other hand, do not appear when the PRE is incubated
with NB extracts in the absence of antibody or in the
presence of AP1, SP1, or USF1 antibodies. These results
indicate that AP2, PuF, SP1, and USF2 are all potential
candidates for interaction with the PRE.
Southwestern blotting with the PRE shows different DNA-
protein interactions among different cell lines and
conditions
To ascertain sizes of proteins that participate in some of
the observed interactions with the PRE, we performed
southwestern blotting with nuclear extracts from NB,
PC12, HeLa and TPA-treated HeLa cells (Figure 3).
Probing with radiolabeled PRE oligomer pairs revealed
that DNA-protein interactions varied among extracts
and were subject to induction. NB nuclear extract (lane
1) had major interactions at approximately 92, 33, 32,
and 23 kDa (the last an extrapolation outside the range
of the size standard). In addition, faint bands appeared
Figure 2 Antibody supershift EMSA of PRE in NB nuclear
extracts. Radiolabeled PRE oligomer pairs were incubated with NB
cell nuclear extracts (lane 1) and with extracts in the presence of
antibodies against transcription factors AP1 (lane 2), AP2 (lane 3),
PuF (lane 4), AP2 + PuF (lane 5), SP1 (lane 6), USF1 (lane 7), or USF2
(lane 8). Arrows indicate seven major bands..
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extract (lane 2) also had a 33 kDa/32 kDa doublet but
lacked a 92 kDa interaction. Instead, an interaction at
approximately 60 kDa appears.
PC12 also had weaker interactions at 92, 39, and 23
kDa. HeLa nuclear extract (lane 3) shared interactions at
approximately 92 and between 33 and 32 kDa, with
fainter bands at 64, 60, 51, 39, and 23 kDa. Induction of
HeLa with TPA (lane 4) resolved the 33/32 kDa band
into a doublet and reduced the strength of weaker inter-
actions. Comparison of the observed southwestern bands
with molecular weights of predicted transcription factors
suggests the possibility that several of the predicted candi-
date transcription factors may bind to the PRE (Table 2).
These comparisons were based on a ±10% adjustment
to the calculated southwestern band kDa. Of the poten-
tial DNA-TF interactions, several appear for all nuclear
extracts. These are AP2, Msx1, and USF1. A few are
unique to human neuroblastoma nuclear extracts, spe-
cifically Pax4a, USF2, and BTEB2. There is no signal that
can be assigned to PuF subunits, which would be around
17kDa in weight. This may be an artifact of the specific
gel’s polyacrylamide percentage. However, the band VI/
VII doublet could correspond to PuF dimers. In general,
the southwestern does not exclude conclusions of our
EMSA-based assays.
Mutating the PRE alters DNA-protein interaction
To more specifically determine those sequences within
the PRE that participate in gene regulation, we had
synthesized a series of oligomer pairs that deleted one or
more of the transcription factor sites we predicted to be
in the PRE. These mutant oligomers were used for EMSA
(Figure 4A, B) in both NB (lanes 1–8) and PC12 (lanes 9–
16) cell nuclear extracts. Mutations resulted in both
quantitative and qualitative alterations in DNA-protein
interaction as determined by EMSA. Densitometry scans
revealed that, at least for some mutants, such as M6, two
partially overlapping bands appeared (Figure 4A, lane 7),
and the wildtype oligomer pair has an extended trailing
end to its peak, suggesting that wildtype binding is to
more than one interaction partner. Semi-quantitative ana-
lysis, therefore, was done for all samples on each individ-
ual peak (division between peaks shown by dashed line in
Figure 4A-C).
Starkly visible qualitative differences were restricted to
mutants M1, M4 and M6. The M1 mutants’ predicted
binding sites had lower affinity for AP2, GATA1, PuF,
one of the two predicted SP1 transcription factor sites,
and a downstream GC box. The M4 mutant is predicted
to lose the shared GATA1/GATA2 site and the down-
stream SP1 site, The M6 mutant loses a predicted binding
site for zeste homolog/TCERG1. In the case of the first
two mutants, the major DNA-protein interaction pro-
duct’s migration was reduced compared to the wildtype
oligomer pair’s primary interaction product (Figure 4C).
Analysis of relative migration rates for the wildtype oligo-
mer pair showed that migration of the DNA-protein inter-
action products for M1 (lanes 2, 10) and M4 (lanes 5, 13)
were significantly (p<0.05) reduced from the relative mi-
gration rate of wildtype oligomers (lanes 1, 9). The M6
mutation (lanes 7, 15) produced two major DNA-protein
interactions in EMSA. The peak of the slower-running
Figure 3 Southwestern blot of PRE vs. cell line nuclear extracts.
Nuclear extracts from cell lines NB (lane 1), PC12 (lane 2), HeLa (lane
3), and HeLa treated with TPA (lane 4) were separated on 10%
SDS-PAGE and transferred to nitrocellulose membrane. Membrane
was probed with radiolabeled PRE oligomers. Blot photographs were
size-equalized by use of the same lot of protein standards. Major
bands are indicated with solid arrows. Minor bands are indicated
with dotted-line arrows.
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not NB cells.
Samples were processed and analyzed in triplicate and
films densitometrically scanned. Densitometry results
were normalized by subtracting the mean peak value for
a single film and dividing by standard deviation for the
film. For data presentation purposes, this was adjusted
by subtracting the standardized value of “wildtype”,
which sets “wildtype” value to 0 (Figure 4D–G, Tables 3,
4). Adjusted data were analyzed by ANOVA followed by
Dunnett’s two-tailed t. Hedges g standard pairwise effect
sizes [43], using mean square error for pooled standard
deviation, were calculated for each variant vs. wildtype
PRE (Tables 3, 4).
Analysis revealed differences between mutation
effects on each band’s signal strengths. Specifically, for
band I (the slower-migrating band), the M1 mutant had
significantly higher adjusted signal than wildtype in NB
(Figure 4D, Table 3) nuclear extract. M2 in NB and
PC12 extracts had significantly lower adjusted signal
than did wildtype (Figure 4E, Table 4). For the domin-
ant wildtype PRE EMSA band (band II), M3 and M7
had significantly higher signal than wildtype in NB
(Figure 4F, Table 3) and PC12 (Figure 4G, Table 4) nu-
clear extracts, while M1 and M4 had significantly
reduced signal in NB and PC12 extracts.
Mutating the PRE in a reporter gene system produces
specific functional differences
To reveal connections between DNA-protein interac-
tions and expression in mutations of the PRE, we con-
structed seven plasmids that mutated the PRE sequence
identically to the mutant PRE oligomers. These cons-
tructs were all based on pβXbB [17], which contains a
promoterless CAT gene sequence under the control of
an XbaI/BamHI fragment of the rhesus monkey APP
gene promoter and 5
0-UTR, specifically −309/+104, with
+1 being the transcription start site (Figure 5A). Clones
were transfected into PC12 and NB cell cultures as
described herein.
ELISA results of the functional assay were adjusted for
β-gal levels and made relative to wildtype = 1. Adjusted
results were compared to wildtype by Dunnett’s t, and
Hedges g was calculated for each pairwise comparison
(Tables 3, 4). Functional mutation effects in NB cells
(Figure 5B, Table 3) were distinct from PC12 (Figure 5C,
Table 4). In NB cells three mutants (M1, M5, and M6)
had reduced reporter expression compared to wildtype,
and mutant M3, had greater adjusted reporter expres-
sion than wildtype. In PC12 cells, mutants M1, M4, M5,
and M6 had significantly lower CAT protein levels than
wildtype. Mutating predicted locations of putative tran-
scription factor sites in the PRE significantly alters re-
porter gene expression. These results were consistent
between cell lines for the M1 and M5 mutants.
Semiquantitative EMSA and ELISA specifically correlate by
PRE mutants
We compared EMSA and ELISA results by meta-analysis
of pairwise Hedges g for ELISA and EMSA results vs.
wildtype (Figure 6). For both NB and PC12 cells/ nuclear
extracts, much weaker correlations were found between
EMSA band I and ELISA signal (Figure 6A, B). Stronger
correlations existed between EMSA band II and ELISA
signal in both cell lines (Table 5; Figure 6C, D). Signifi-
cance was estimated as chance that r ≠ 0 by bootstrap
(500,000 repetitions).
The percent overlap between the two bootstrap distri-
butions within a single cell line was also calculated. The
difference between correlations of EMSA I to ELISA vs.
EMSA II to ELISA was more distinct in PC12 cells, with
a 16% overlap between the two bootstrap distributions.
In NB cells, the two bootstrap distributions overlapped
by 34%. While there may be some indication of a direct
relationship between EMSA band II signal and reporter
ELISA results, we suggest caution in interpreting correl-
ation meta-analysis. In addition to modest, at best, esti-
mations of significance, EMSA bands I and II did not
distinctly resolve on autoradiographs in many variants
we studied, including wildtype (Figure 4). In addition,
cell cultures used for ELISA and nuclear extracts used
for EMSA did not come from the same specific cultures.
Even with bootstrap estimation, they essentially repre-
sent correlations of averaged results from each assay.
Nevertheless, we accept the possibility that some cor-
respondence exists between altering the strength of the
major DNA-protein interaction for the wildtype olig-
Table 2 Putative TF sites from southwestern blot based
on estimated kDa of bands
Band
a kDa Nuclear extracts
b Corresponding TF
c
I9 2 NB, HeLa, HeLa+TPA SP1
II 64 NB, HeLa, HeLa+TPA R
III 60 PC12, HeLa, HeLa+TPA USF1, TCERG1
IV 51 NB, HeLa USF1, AP2, GATA1, GATA2,
TCERG1
V 39 NB GATA1, USF1, AP2, Pax4a,
USF2
VI 33 NB, PC12, HeLa, HeLa +
TPA
USF1, AP2, Msx1
VII 32 NB, PC12, HeLa, HeLa +
TPA
USF1, AP2, Msx1
VIII 23 NB BTEB2
aBands named in bold face are described as “major” in Figure 2.
bNuclear extracts for which the band appears in the southwestern.
cTF correspondence is based on calculated band kDa ±10%.
Lahiri et al. BMC Genomics 2013, 14:68 Page 7 of 28
http://www.biomedcentral.com/1471-2164/14/68Figure 4 (See legend on next page.)
Lahiri et al. BMC Genomics 2013, 14:68 Page 8 of 28
http://www.biomedcentral.com/1471-2164/14/68omer pair (band II) and functional effects in reporter
fusion assay.
Mutating the PRE produces cell line-specific and inducible
effects, as measured by EMSA
To further investigate possible cell line/type-specific
effects of the PRE, three mutants, specifically M1, M4,
and M6, plus the wildtype PRE, were used as probes in
EMSA with nuclear extracts from NB, PC12, human
glioblastoma-astrocytoma (U373), HeLa or mouse embryo
fibroblast (NIH3T3) cells. In addition, these oligomers
were assayed with EMSA with nuclear extracts from
HeLa, or NIH3T3 cells that had been subject to induction
conditions, such as TPA treatment, serum starvation or
induction with cytokines such as interleukin-6 (IL6) or
transforming growth factor β (TGFβ) (Figure 7). Three ap-
parent bands, marked N (“null”/“zero”), I, and II, appeared
among the various nuclear extracts, although no extract/
mutant combination had all three bands. In nuclear
extracts from NB cells (Figure 7, lanes 1–4), DNA-protein
interactions were obtained as reported in 3.1. Wildtype
oligomers produced a single strong interaction (lane I,
band II). The M1 and M4 oligomer pairs each had an
interaction that migrated more slowly than did the wild-
type (lanes 2–3), while M6 had a mixed interaction, with
bands that migrated both at the same rate as produced by
wildtype and as by M1 (lane 4) oligomer pairs. The PC12
extracts (lanes 5–8) produced a pattern similar to that
found with NB extracts, excepting that the DNA-protein
interaction with M4 (lane 7) has a stronger “leading” edge
to its band while the interaction with M6 has a weaker
“trailing” peak in the band doublet (lane 8).
Interactions observed with U373 extracts (lanes 9–12)
bore some resemblance to those observed with NB and
PC12 nuclear extracts specifically for wildtype (lane 9)
and M1 (lane 10). However, the M4 and M6 DNA-
protein interactions (lanes 11, 12) were noticeably differ-
ent from both NB and PC12. DNA-protein interactions
seen with untreated HeLa nuclear extracts (lanes 13–16)
did not apparently vary among PRE variants, but treat-
ment of HeLa with TPA (lanes 17–20) resulted in a pat-
tern of interactions that was more similar to those with
NB and PC12 extracts.
Untreated HeLa (lanes 13–16) DNA-protein interac-
tions were unlike those found in the other cell lines sur-
veyed. They had an additional band that migrated more
(See figure on previous page.)
Figure 4 EMSA of wildtype and mutant PRE oligomers and semiquantitative analysis of EMSA. Wildtype and mutant PRE oligomers (M1-
M7) were incubated with A. NB and B. PC12 nuclear extracts were analyzed on non-denaturing PAGE. Samples were analyzed in triplicate; figure
presents a representative gel for each. Bands “I” and “II” as described in the main text are indicated. Dashed line indicates division made between
band I and band II for densitometry purposes. C. Cross section of EMSA lanes. ImageJ software was used to evaluate densitometry of scanned
films from EMSA of NB and PC12 nuclear extracts with various PRE variant oligomer pairs. Profiles of peaks for each PRE variant from a typical gel
are shown. Dashed line indicates boundary between band I and band II for densitometry purposes. D–G. Densitometry readings for EMSA films
were normalized to standard deviations and average readings for “wildtype” signal within each film as described in the main text. Normalized
readings were compared to the wildtype reading by Dunnett’s multiple t. Means significantly different at p > 0.05 indicated by “*”. D. Band I, NB
extract. E. Band I, PC12 extract. F. Band II, NB extract. G. Band II, PC12 extract.
Table 3 Adjusted/normalized ELISA and EMSA signals in NB cells and extracts
Variant EMSA
a
Band I Band II ELISA
a
Rel. PRE = 0 g Rel. PRE = 0 g Rel. PRE = 1 g
PRE 0.00 ± 0.18 0.00 ± 0.82 0.00 ± 0.11 0.00 ± 0.82 1.00 ± 0.17 0.00 ± 0.82
M1 1.81
c ± 0.24 3.24 ± 0.99/0.95 −1.76
c ± 0.11 −4.86 ± 1.29/1.31 0.37 ± 0.05 −3.12 ± 0.92/0.96
M2 −1.33
b ± 0.26 −2.39 ± 0.79/0.84 −0.43 ± 0.13 −1.18 ± 0.62/0.66 0.81 ± 0.12 −0.91 ± 0.60/0.63
M3 0.60 ± 0.27 1.07 ± 0.65/0.61 0.79
b ± 0.23 2.19 ± 0.80/0.76 1.69
b ± 0.13 3.40 ± 1.02/0.98
M4 0.40 ± 0.38 0.72 ± 0.62/0.59 −1.62
b ± 0.09 −4.48 ± 1.21/1.23 0.89 ± 0.02 −0.52 ± 0.58/0.60
M5 −0.28 ± 0.21 −0.51 ± 0.58/0.60 0.07 ± 0.22 0.19 ± 0.58/0.57 0.34
b ± 0.08 −3.24 ± 0.95/0.99
M7 0.27 ± 0.31 0.48 ± 0.60/0.58 −0.61 ± 0.12 −1.68 ± 0.68/0.73 0.16
b ± 0.12 −4.14 ± 1.13/1.16
M7 1.00 ± 0.42 1.78 ± 0.74/0.70 0.87
b ± 0.35 2.41 ± 0.84/0.79 1.04 ± 0.09 0.18 ± 0.58/0.57
F (p) Ψ
d F (p) Ψ F (p) Ψ
ANOVA 9.79 (< 0.01) 1.65 ± 0.82/0.62 26.54 (< 0.01) 2.72 ± 1.09/0.97 21.20 (< 0.01) 2.43 ± 1.01/0.88
aData is mean ± standard error of the mean (SEM). EMSA is normalized to wildtype = 0. ELISA is relative to wildtype = 1. SEM reported as (x/y as upper/lower) is
asymmetrical due to noncentrality of standardized effect size measures [43].
bSignal significantly different from wildtype at p < 0.05.
cELISA and EMSA signal both significantly different from wildtype at Bonferroni-adjusted p < 0.05.
dΨ as estimate ± 95% confidence interval.
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http://www.biomedcentral.com/1471-2164/14/68slowly than seen for other cell line nuclear extracts.
Interaction was very weak with the wildtype oligomer
(lane 13), and it appeared as a doublet. The M1 mutant’s
interaction was a single band (lane 14), while M4 and
M6 interactions were doublets (lanes 14–16).
S e r u ms t a r v a t i o no fN I H 3 T 3( l a n e s2 5 –28) may have
slightly reduced interactionw i t ht h eM 4m u t a n t( l a n e
27) but appeared to have no other effect. Treatment of
NIH3T3 with IL6 (lanes 29–32) increases DNA-protein
interaction with the M6 oligomer (lane 32, band I). Of
particular interest, treatment of NIH3T3 with TGFβ
(lanes 33–3 6 )b r o u g h ta b o u tad r a m a t i cs h i f ti nD N A -
protein interaction bands for the wildtype PRE and all
three mutants. While interaction was visibly weaker
Table 4 Adjusted/normalized ELISA and EMSA signals in PC12 cells and extracts
Variant EMSA
a
Band I Band II ELISA
a
Rel. PRE = 0 g Rel. PRE = 0 g Rel. PRE = 1 g
PRE 0.00 ± 0.23 0.00 ± 0.82 0.00 ± 0.1 0.00 ± 0.82 1.00 ± 0.11/0.09 0.00 ± 0.82
M1 1.25 ± 0.92/0.78 1.77 ± 0.74/0.69 −1.38
c ± 0.07 −5.56 ± 1.44/1.45 0.39
c ± 0.02 −6.84 ± 1.73
M2 −0.91 ± 0.11 −1.43 ± 0.65/0.69 −0.14 ± 0.18 −0.56 ± 0.58/0.60 0.67 ± 0.05/0.04 −2.05 ± 0.74/0.78
M3 0.56 ± 0.07 0.84 ± 0.63/0.60 1.20
b ± 0.14 4.82 ± 1.30/1.28 0.83 ± 0.18/0.12 −0.8 ± 0.59/0.62
M4 0.61 ± 0.48/0.44 0.91 ± 0.63/0.60 −1.04
c ± 0.11 −4.20 ± 1.15/1.17 0.45
c ± 0.01 −5.33 ± 1.39/1.4
M5 0.16 ± 0.12 0.25 ± 0.58/0.57 0.30 ± 0.07 1.23 ± 0.67/0.63 0.43
b ± 0.04/0.03 −5.69 ± 1.47/1.48
M6 0.27 ± 0.06 0.41 ± 0.59/0.58 −0.25 ± 0.13 −1.01 ± 0.61/0.64 0.43
b ± 0.01 −5.68 ± 1.47/1.48
M7 1.46 ± 0.58/0.52 2.04 ± 0.78/0.73 1.58
b ± 0.19 6.36 ± 1.62 1.03 ± 0.03 0.12 ± 0.58/0.57
F (p) Ψ
d F (p) Ψ F (p) Ψ
ANOVA 4.23 (< 0.01) 1.09 ± 0.78/0.45 58.96 (< 0.01) 4.05 ± 1.49/1.42 29.96 (< 0.01) 2.89 ± 1.14/1.03
aData is mean ± standard error of the mean (SEM). EMSA is normalized to wildtype = 0. ELISA is relative to wildtype = 1. SEM reported as (x/y as upper/lower) is
asymmetrical due to noncentrality of standardized effect size measures [43].
bSignal significantly different from wildtype at p < 0.05.
cELISA and EMSA signal both significantly different from wildtype at Bonferroni-adjusted p < 0.05.
dΨ as estimate ± 95% confidence interval.
Figure 5 ELISA of PRE variant CAT reporter clones in NB and PC12 cells. Functional differences of PRE mutant clones (M1-M7) from wildtype
were assayed in NB and PC12 cells. A.p βXbB were constructed and transfected into NB or PC12 cell cultures as described in the main text.
Cultures were harvested and analyzed by CAT ELISA. ELISA signals were normalized to “wildtype” values and subject to Dunnett’s multiple t.
Means significantly different at p > 0.05 indicated by “*”. B. ELISA of samples from NB cell cultures. C. ELISA of samples from PC12 cell cultures.
Data presented is back-transformed from statistical analysis. Asymmetrical error bars and Dunnett’s t limits are due to Box-Cox transformation,
when used.
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http://www.biomedcentral.com/1471-2164/14/68than for other NIH3T3 based extracts, it very closely
resembled that seen for normal NB (lanes 1–4) and
PC12 (lanes 2–8) extracts.
The PRE is well-conserved within the human genome and
throughout eutherian mammals
To explore the possibility that the PRE is well-con-
served, we examined genomic sequences identified or
putatively identified as proximally upstream of the APP
gene of 35 mammal species that were aligned by Web-
Prank [44] as described herein. Information of the align-
ment was calculated in bits [45,46] and averaged in a
window of 100 nt, which roughly corresponds to the
distance between nucleosomes in chromosomal DNA as
described herein. Examination of the alignment as a
whole revealed that the PRE was well conserved com-
pared to immediately flanking sequences. Adding non-
primate sequences to the alignment did not change
average information content immediately around the
PRE (Figure 8A), but average information content for
the alignment dropped off significantly (p <0.05, Bonfer-
roni adjusted for 4 comparisons) when on either side of
the PRE. Information inversely expresses homogeneity,
Figure 6 EMSA vs. ELISA standardized effect sizes for PRE variants in NB and PC12 nuclear extracts and cultures. EMSA and ELISA results
were used to generate Hedges pairwise g of comparisons of each mutant to wildtype PRE. Data was plotted with EMSA g on X axis and ELISA g
on Y axis. Samples where both EMSA and ELISA signals were significantly different from wildtype at Bonferroni adjusted p < 0.05 are indicated
with corresponding mutant names. Correlations were bootstrapped (repeats = 100000), and frequency distributions of correlation coefficients are
presented as insets. A. EMSA Band I vs. ELISA in NB extract/cells. B. EMSA Band I vs. ELISA in PC12 extract/cells. C. EMSA Band II vs. ELISA in NB
extract/cells. D. EMSA Band II vs. ELISA in PC12 extract/cells.
Table 5 Meta-analysis of PRE and mutant EMSA vs. ELISA
Cell
line
Correlation coefficient of ELISA vs. %
Bootstrapped
correl. overlap
EMSA band I (p) EMSA band II (p)
NB −0.008 (0.489) 0.579 (0.057) 39%
PC12 −0.115 (0.391) 0.752 (0.006) 16%
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http://www.biomedcentral.com/1471-2164/14/68since 100% homogeneity at a given base is maximum
possible score (2 bits) and equal distribution of all four
bases would be 0 bits.
Phylogenetic comparison of the alignment (−326/+202
in the human sequence) led, as expected, to rejection of
the molecular clock hypothesis (Figure 8B). DNA changes
observed within the, admittedly short, region are unlikely
to occur simply through neutral sequence drift. Of par-
ticular interest is that most of the primate sequences
appeared to have a slower-than-typical rate of change vs.
the overall tree while mouse and rat sequences had a
faster-than-typical rate of change. Further detailed exam-
ination was done of the alignment region immediately sur-
rounding the PRE (Figure 9). Alignment was guided by a
tree (Figure 9A) based on current conventional mammal
phylogeny [47-49], as suggested by the WebPrank proto-
col. Sequences were taxonomically weighted as described
herein and homologies between the human sequence vs.
other primates, euarchontoglires, boreoeutheria, eutheria,
and all mammals were calculated for the aligned PRE, as
were sequence logos [46] for these groups (Figure 9B–F).
The PRE remains fairly stable throughout the eutheria,
with no less than 92.3% weighted homology to the human
sequence (Table 6). Adding marsupials to the estimation
reduces homology to 73.8%. Greater aggregate distance
from primates also associates with lower specificity within
the PRE (Table 6)—total information content (essentially
expressing sequence specificity in terms of bits) drops
from 49.04 for primates (including humans) to 39.36 when
all mammal sequences are considered (Table 6). Of par-
ticular interest, the overlapping SP1/PuF site within the
PRE is also well conserved among placental mammals
(Figure 9E). However, the site breaks down when marsu-
pial sequences are included (Figure 9F). Marsupials also
have a 9–10 base insertion within the PRE (Figure 9F–G).
Discussion
The APP gene consists of 18 exons and spans more than
300 kilobases on human chromosome 21 [51]. We
hypothesize that unusually high production of Aβ may
contribute to AD, and this aberrant Aβ production can
be a result of unusually high APP gene expression. The
APP gene is a likely locus for sporadic, late-onset AD,
the most common form of the disease [2,52,53]. Down
syndrome patients invariably develop AD, which may be
due to additional gene dose of the APP gene in the Down
critical region of chromosome 21. In addition, cases of
late-onset AD have increased plasma levels of the forms of
Aβ [54] specifically associated with the disease. Tissue and
cell-type specific expression of the APP gene may also
p l a yar o l ei nA P Pp r o t e i no rA β-related pathogenesis. It
is well established that mutations in the APP coding se-
quence can cause autosomal dominant early onset FAD
[55]. Some analyses of the coding sequence [56] and the
promoter [57] rejected other APP polymorphisms as
predisposing to late onset AD (LOAD). However, there
are reports of promoter polymorphisms that increase risk
for AD in a non-autosomal fashion [58,59], particularly of
Figure 7 EMSA of PRE and selected mutants in NB, PC12, HeLa, NIH3T3, and U373 nuclear extracts. Wildtype oligomers (lanes 1, 5, 9, 13,
17, 21, 25, 29, 33) and oligomers for the M1 (lanes 2, 6, 10, 14, 18, 22, 26, 30, 34), M4 (lanes 3, 7, 11, 15, 19, 23, 27, 31, 35), and M6 (lanes 4, 8, 12,
16, 20, 24, 28, 32, 36) were labeled with γ−
32P-ATP, incubated with NB (lanes 1–4) PC12 (lanes 5–8), U373 (lanes 9–12), HeLa (lanes 13–16), HeLa +
TPA (lanes 17–20), NIH3T3 (lanes 21–24), NIH3T3 + serum restriction (lanes 25–28), NIH3T3 + IL6 (lanes 29–32), and NIH3T3 + TGFβ (lanes 33–36)
nuclear extracts, and analyzed on nondenaturing PAGE, and gels subject to autoradiography.
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Figure 8 Multiple sequence alignment of APP upstream regions and test of molecular clock. DNA sequences from 20 mammal species
were downloaded from GenBank and aligned with WebPrank as described in the main text. A. Average information content in a window of 100
nt and 95% confidence intervals were calculated for primates, euarchontoglires, boreoeutheria, eutheria, and mammals. B. Alignment was used as
input for parsimony/FITCH combined phylogeny estimation as described in the main text. This produced a bifurcating non-ultrametric tree,
although some branch lengths = 0. The tree was artificially rooted between marsupials and eutheria, and root-to-tip distances for each species
calculated. Root-to-tip distances were compared to mean root-to-tip distance for the entire tree. Individual distances that differed from the mean
distance (vertical solid line) ± the 95% (Bonferroni adjusted for 35 comparisons) confidence interval (vertical dashed lines) were counted as
“significant”. Distances that significantly exceeded the mean indicated by “†”. Differences significantly lower than the mean indicated by “*”.
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Figure 9 (See legend on next page.)
Lahiri et al. BMC Genomics 2013, 14:68 Page 14 of 28
http://www.biomedcentral.com/1471-2164/14/68two polymorphisms in the APP promoter associated with
AD pedigrees [23].
In addition, the following results strongly implicate the
role of promoter elements in AD. 1) In a genome screen
of 292 sib-pairs with LOAD, Hardy’s group identified 12
loci with lod-scores >1 including a region on chromo-
somes 21 [60]. 2) Using non-parametric linkage meth-
ods, Duke’s group showed that a locus predisposing to
LOAD might reside in this region of chromosome 21
[61]. 3) Levels of Aβ correlate to cognitive decline in
predementia and dementia [62]. 4) Genetic analysis of a
case of DS due to non-disjunction suggested triplication
of APP in the pathogenesis of AD in Down syndrome
[63]. 5) Younkin’s group analyzed plasma Aβ in 180
first-degree relatives of LOAD patients and in 82 age-
matched controls. This analysis showed highly signifi-
cant increase in plasma Aβ40/42 in the relatives as com-
pared to controls [64,65].
Serial deletion analysis of the APP promoter has revealed
several regulatory elements [14,17]. The APP promoter is
regulated by several factors, including but not necessarily
limited to nerve growth factor, fibroblast growth factor,
and interleukin-l [20,21]. Copper depletion downregulates
APP promoter activity [22]. Various groups have reported
other transcriptional elements within the first 100 nt from
TSS of the APP gene [19,34,66,67]. This includes regulation
of APP promoter expression by two GC-elements [67], the
zinc finger protein CTCF [66], and upstream stimulatory
factor [19].
We previously reported discovering a 30 nt (−76/−47)
fragment from a deletion series of the APP promoter
with different effects depending upon cell line [27]. Our
discovery was independently paralleled by other workers,
who have noted a fragment of the APP promoter at −55/
−33 by DNAse protection assay. This fragment was pre-
dicted to contain AP1 and AP4 binding sites, but both
were experimentally excluded [15]. Furthermore, dele-
tion of a −54/−42 fragment of the APP promoter resulted
in reduced expression of reporter fusion clones [68]. In
addition, deletion of a −77/−47 fragment resulted in
reduced reporter fusion expression in rat primary embry-
onic hippocampal neurons [69], which was similar to our
own observation of the effect of deleting the PRE in ro-
dent cell lines and opposite what we observed in human
cell lines [27]. This other work essentially concluded that
USF was the responsible agent for regulation through this
APP promoter fragment, although it did propose but not
test a putative SP1 binding site. We do not dispute that
USF may play an important role in APP proximal protein
regulation but investigate the possibility that other factors
and cofactors also operate on this sequence.
We sought to more fully characterize the activity of the
PRE as a component of the 5
0-flanking region of the APP
gene. Transcription factor binding activity was studied by
EMSA with human tissue nuclear extracts, including
extracts from human brain, followed by EMSA in four dif-
ferent cell line nuclear extracts under different conditions
of stimulation or induction. Binding of specific TFs was
tested by competition EMSA and by antibody-supershift
EMSA. We also used Southwestern blotting to estimate
molecular weights of interaction partners with the PRE
and compared these with candidate transcription factors.
Table 6 Analysis of APP proximal promoter region multiple sequence alignment
n PRE PuF site
Ri
c Homology
d Ri Homology
Primates 9 49.04±3.81 95.1%±1.7% 11.31±0.93 98.2%±2.4%
Euarchontoglires 18 48.48±3.02 92.8%±1.8% 11.35±0.49 92.5%±4.2%
Boreoeutheria 27 50.58±1.50 93.2%±1.6% 11.72±0.27 92.1%±4.2%
Eutheria 32 50.29±1.29 90.8%±1.9% 11.19±0.23 91.5%±4.5%
Mammals 35 39.36±2.85 76.6%±2.8% 8.64±0.48 73.8%±6.2%
cRi: Information content/specificity ± 95% confidence interval.
dHomology: Average percent ± 95% confidence interval.
(See figure on previous page.)
Figure 9 Taxonomic guide tree, sequence logos for the PRE for five ascending clade levels from primates through mammals, and DNA
alignment immediately surrounding the PRE. A. The guide tree used for multiple sequence alignment with WebPrank [44]. Guide tree was
assembled based on recent phylogenetic analysis of higher organization of mammals [46-49]. B–F. Sequence logos were calculated by
conventional methods [50], with sequences taxonomically weighted as described in the main text. Membership in successively nested clades for
each species is indicated. The location of the PuF/SP1 site is indicated for all logos. Error bars represent estimated standard deviations of Ri. Logos
were calculated for B. primates, C. Euarchontoglires, D. Boreoeutheria, E. Eutheria, and F. Mammals. Sequence specificity for the PRE and the PuF/
SP1 site are preserved throughout placental mammals. G. The region of the alignment immediately around the PRE. The PRE is indicated with a
solid box, and the PuF/SP1 site is indicated with dashed lines.
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http://www.biomedcentral.com/1471-2164/14/68We have determined that the PRE has tissue specifi-
city, showing greater DNA-protein interaction with brain
and lung extracts than with liver or heart extracts. In
addition, the PRE has cell line-specific DNA-protein inter-
actions with cell nuclear extracts, differing among U937,
HeLa, U373, PC12, NIH3T3 cell lines. These interactions
are subject to reduction, elimination, or qualitative change
by conditions such as hypoxia, SR, and induction with
TPA or IFN-γ), IL6, or TGFβ. Our results suggest that the
−76/−47 region binds to a protein that is upregulated in
serum starvation, and downregulated in hypoxia. Because
serum starvation contributes to the induction of apop-
tosis, these results suggest a role of the 30-nt proximal
APP promoter element in enhanced apoptotic neuronal
cell death.
Competition EMSA and antibody-supershift EMSA
confirmed predicted interactions between the PRE and
AP2, while antibody-supershift EMSA confirmed inter-
action between the PRE and AP2, PuF, SP1, and USF2.
Competition and supershift EMSA appear to contradict
each other regarding SP1. Possible biological explana-
tions could include sufficiently high affinity within the
PRE for SP1 to overcome competition with the particu-
lar commercial probe used. High PRE-SP1 affinity could
result in a “negative” competition result but a positive
supershift, since the supershift is meant to detect SP1
when bound to the target DNA. Alternatively, our super-
shift may be interacting with an SP1-like transcription
factor that binds the PRE but has a lower affinity with
the consensus SP1 site in the commercial competition
oligomer. Southwestern blotting indicated possible inter-
actions between the PRE and AP2, SP1, and USF2,
among other TF. It also admitted the possibility of PRE-
PuF dimer interaction.
We mutated the PRE and highlighted a specific effect of
the sequence that included the predicted PuF/SP1 binding
site. Our mutant expression evidence tends to agree with
our EMSA evidence. Of the mutants characterized, M1
was the most consistent in response across NB and PC12x
cells and nuclear extracts. Specifically, semi-quantitative
EMSA with M1 probe resulted in significant signal loss at
the band position that corresponded closely to the major
band of wildtype PRE EMSA in both NB and PC12 nu-
clear extracts. Likewise, M1 mutant promoter/reporter ex-
pression clones resulted in significantly reduced levels of
CAT reporter protein in both NB and PC12 cells. The M1
mutant deleted the predicted PuF site and both predicted
SP1 sites in the PRE.
We note that M2 and M4 each also deleted a single
predicted SP1 site, the specific site differing between M2
and M4. EMSA analysis of these two mutants showed
that M4 consistently had reduced EMSA interaction at
band II, while M2 did not. However, CAT reporter levels
were not consistently altered between cell types. There-
fore, our mutation analysis confirms our earlier conclu-
sion that the PRE is most likely to function as a site of
PuF and SP1 activity. Disruption of the shared PuF/SP1
site in our system resulted in reduced levels of reporter
gene product, which appears to contradict part of our
proposed model. However primary sequence disruption
of the site would influence both PuF (repressive) and
SP1 (stimulatory) interaction very strongly. In addition,
disruption of the AP2 site also resulted in loss of EMSA
signal, suggesting that the PRE may also function under
induction as well as constitutively.
Currently, two DNA sequence polymorphisms have
been reported for the PRE, specifically rs200621906 and
rs201592736 [37]. Each is predicted to alter potential
TF binding sites within the PRE (Table 7). Of particular
note, rs201592736 may interfere with the PuF site. In
addition, potentially interesting sites were created, in-
cluding glucocorticoid/progesterone receptor (GR/PR),
NF1-like enkephalin nuclear transcription factor 1 (NKTF1)
retinoic acid receptor γ (RARγ), and zinc finger E-box-
binding homeobox 1 (ZEB1),. Glucocorticoid levels are well
associated with AD risk [70]. Progesterone supplementation
has been linked to more rapid age-related cognitive decline
in post-menopausal women [71,72]. Elevated levels of
enkephalin contribute to neurological impairment and tau
phosphorylation in AD model animals [73]. Upregulation
of enkephalin accompanied by upregulation of APP due to
an SNP in the PRE may overwhelm natural defenses against
neurodegeneration. RARs direct APP processing toward
the non-pathogenic α pathway [74], and it is conceivable
that a feedback mechanism that results in RAR-mediated
overproduction of APP in a natural PRE mutant may
overwhelm this process. ZEB1 interacts with TGFβ [75],
and TGFβ is implicated in AD pathogenesis [76,77]. The
rs201592736 SNP approximates our M2 mutant, while
rs200621906 approximates M4. Combining both poly-
morphisms approximates the TF deletion effects of M1,
which showed significant Bonferroni-adjusted reductions in
both EMSA and CAT reporter by meta-analysis. Population
frequency of these SNPs has not been published, and it has
not been yet determined if they occur as a haplotype or in-
dependently. It should be cautioned that, although they
have interesting potential TF site changes, functional asso-
ciation with any disease state has also not been determined.
The PRE is strongly conserved in placental mammals,
particularly the PuF/SP1 overlapping site. In addition, this
conservation occurs in a promoter region that has under-
gone significant non-neutral (i. e., non-molecular clock)
change. In particular, primate and mouse/rat sequences
diverge the most from each other in our root-to-tip ana-
lysis, but with far less difference when considering the
PRE, specifically. We propose that this particular short
segment of the APP proximal regulatory region has been
specifically maintained, as would be expected of an active
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AD-associated gene promoters, such as for APOE,h a v e
important differences between mouse and human [25].
Likewise, we have reported both differences and similar-
ities between human and rat cell line responses to func-
tional promoter deletion clones of the human MAPT
promoter [26]. Such overall differences can be put to use
in identifying potentially critical regions of similarity, such
as the PRE within the APP promoter.
Although two SNPs have been reported in the
human PRE, it is unlikely, given their obscurity in the
literature, that these would be common enough to ex-
plain a large proportion of sporadic AD. We propose
that the majority of etiologically important PuF vs. SP1
disruption in the PRE would be due to environmental
influences on epigenetic markers. The naturally-
occurring SNPs could serve as a potential test bed,
given their similarity in terms of TF site disruption to
some of our synthetic mutants. It is potentially more
interesting that the Puf/SP1 site consists primarily of
GG and GGG sequences, which are particularly vul-
nerable to DNA oxidation [78]. While SP1 activity is
sensitive to epigenetic DNA modification [79], and
PuF operates in repair of DNA damage [80], relative
effects of DNA oxidation upon each protein’s activity
as a transcription factor have not been established.
Likewise, CpG dimers (sites of cytosine methylation)
are immediately adjacent to the PuF/SP1 site. Thus, in
our system, while disrupting both PuF and SP1 activity
by primary sequence mutation may result in overall re-
duction in reporter levels, environmentally-induced
epigenetic alterations to the shared target DNA se-
quence may favor SP1 stimulation over PuF inhibition.
In light of the knowledge that overall PuF activity may
be reduced in AD, we do not suggest that epigenetic
modification of the PRE would be the sole cause of
the disorder. Rather, it would contribute to disruption
of normal APP gene expression that would accompany
AD. Feedback mechanisms between APP and other
misregulated AD associated genes may serve to also
reduce PuF activity in concert with direct disruption of
APP-PuF interaction. We admit that our current as-
signment of PuF and SP1 to active status within the
PRE has not yet been directly tested.
Mammalian PuF is associated with inhibition of inva-
sive metastasis [81-84] and stimulation of normal cell
proliferation [85,86]. PuF kinase activity was reduced in
human brain in Alzheimer’s disease and Down syndrome
[87]. Total APP mRNA is elevated in AD brain, specific-
ally KPI(+) isoforms [88]. APP gene expression and SP1
activity are increased in aging primate brains [31]. SP1-
DNA interaction and APP expression in mouse brains
are increased in a latent fashion by early-life dietary ad-
ministration of Pb [29]. We suggest an antagonistic role
between PuF and SP1, specifically that PuF may serve to
downregulate APP gene expression via the PRE in vivo,
and increases in effective SP1 activity, due to increased
SP1 levels, interference in PuF-DNA interaction at the
PRE, or decrease in PuF levels, for example, may over-
whelm PuF regulation.
The PuF transcription factor/kinase was discovered in
the context of inhibiting metastasis [28]. Such inhibition
included through interaction with the MYC gene pro-
moter [89,90]. Later, PuF was determined to also func-
tion as a kinase independently of its TF activity [91]. PuF
TF activity was determined to not only act to inhibit me-
tastasis, but to also operate in non-metastatic cell prolif-
eration [85,86]. In addition to cell proliferative activity,
PuF regulates insulin secretion from pancreas islet cells
[92], providing another molecular link underlying the
recently-proposed metabolic-cognitive syndrome that may
unite metabolic and neurodegenerative disorders [93]. We
propose that these aspects of PuF may prove important in
understanding both AD pathogenesis and the possibility
that a role may be played by APP gene products in onco-
genesis. Of greater interest is that PuF has already been in-
directly linked to AD before our work with the PRE. PuF
interacts with calcium/calmodulin-dependent protein kin-
ase II inhibitor 1 (CAMK2N1) [94]. CAMK2N1 is, itself, a
potent inhibitor of calcium/calmodulin-dependent protein
kinase II (CAMK2), which is a mediator of learning and
memory [95]. CAMK2 is currently a target of several anti-
AD drugs under investigation [96].
Of particular note is that the PRE exists within a DNAse
I hypersensitive region [97], and PuF activity is modulated
by the presence or absence of a DNAse I hypersensitive
region [87]. Likewise, among its amazing variety of func-
tions [98,99], the APP protein is a ferroxidase and
Table 7 Natural SNP in the PRE
SNP Sequence Sites deleted Sites created
rs201592736 5’-TCGGGTGCCGAGCGAGGTGGGCCGGATCAG-3’ AP2, GC Box (I)
a, GATA1, PuF RARγ, ZEB1
rs200621906 5’-TCGGGTGCCGAGCGGGGTGGGCCAGATCAG-3’ AP2, GC Box (II), SP1 (II)
b ENKTF1, GR/PR,
both 5’-TCGGGTGCCGAGCGAGGTGGGCCAGATCAG-3’ AP2, GC Box (both), PuF, SP1 (II) ENKTF1, GR/PR, RARγ, ZEB1
aTwo distinct GC boxes were identified in the wildtype PRE sequence and are designated as “I” and “II”.
bTwo distinct SP1 sites in addition to the GC boxes were identified in the wildtype PRE sequence and are designated as “I” and “II”.
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http://www.biomedcentral.com/1471-2164/14/68activates ferroportin to export iron from neurons [100].
Iron chelation reduces APP protein levels through the
APP mRNA 5’-UTR [101], and this is reversed by iron
supplementation. Conversely, overexpression of APP
results in reduced iron content and increased oxidative
stress in human neuroblastoma cells [102]. Although it
has also been shown that abnormally high levels of iron
accumulate in specific brain regions in AD, particularly
within and around amyloid plaques [103], this is not para-
doxical, since plaque-associated iron would be extracellu-
lar and could be in part due to overactivity of APP in iron
transport. In addition, faulty iron metabolism has been
strongly linked to cancer and neoplasia, specifically
through ferroportin activity [104], and increased serum
iron is associated with greater risk for oxidative damage to
DNA [105]. Of particular interest for a possible oncology/
APP association is that expression of the APP gene in re-
sponse to iron chelators distinctly differed between neo-
plastic and normal cell lines [106]. In cancer patients,
increased APP gene expression was more common in
tumor tissue of oral squamous cell carcinoma patients
than in non-cancerous matched tissue samples. More im-
portantly, in those patients who had elevated APP expres-
sion, survival at 24 months was 48% vs. 82% for patients
with non-elevated APP expression [107]. This suggests
that PuF may exert anti-metastatic properties by, in part,
altering levels of APP expression, reducing overall results
of APP protein’s ferroxidase activity and modulating
cancer risk.
Basal activity of the APP promoter is greatest in neural
origin cell lines, and several promoter elements close to
the PRE are important for this activity [108]. For example,
the APP promoter contains binding sites for important
TFs, such as purine-rich element binding protein-α (PURα)
[109] and early growth response 1 (EGR1) [110]. Notably,
there is a high expression of PURα and EGR1 in neurons
during brain development and in the adult brain, and nega-
tive regulation of APP gene expression by PURα [109].
Conclusions
Interference with TF binding to the PRE in the context
of the complete APP promoter could serve to deregulate
APP production. Deletion of the PRE from a complete
series of APP promoter clones resulted in a 3 to 4 fold
gain of promoter activity in NB cells as measured by
levels of reporter gene product [27]. While AP2 and
USF2 (implicated in our antibody supershifts) are gener-
ally stimulatory factors, the normal function of PuF is
usually inhibitory of pathogenic cell proliferation, specif-
ically metastasis [83,84].
In addition to inhibiting metastasis, PuF serves to
induce normal cell proliferation [83,84]. The APP
PRE
PuF
+1
Aβ sAPPβ
sAPPα CTFα
Aβ sAPPβ
sAPPα CTFα
GGGTGGG
PRE
+1
GGGTGGG *
A: Normal
B: Pathogenic
SP1
PuF SP1
*
Figure 10 Model of Antagonistic PuF vs. SP1 regulation of the APP gene and disruption in AD. A. Non-pathogenic APP expression, levels
regulated by PuF. In normal brain, PuF would compete with SP1 at the PRE and result in normal levels of APP mRNA and protein. Aβ would be
restricted to non-pathogenic concentrations. B. Pathogenic APP expression resulting from disruption of PuF regulation of the PRE. Disruption of
the PRE, such as through environmentally induced DNA oxidation at GG dimers, “*”, may reduce affinity of the PRE for PuF more severely than for
SP1. Effective SP1 activity then serves to upregulate APP expression levels beyond a pathogenic threshold.
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tive in the “neuronal pruning” stage of brain develop-
ment, wherein neurons in the early brain are
selectively removed after rapid proliferation [111]. In
addition to neurogenesis, PuF homologues regulate
early morphological development [112]. Thus, as PuF
serves to stimulate non-pathogenic cell proliferation,
and APP can act to reduce cell proliferation, it is rea-
sonable to propose the possibility that PuF acts to
downregulate APP expression under normal circum-
stances, and interference in PuF regulation through
the PRE could serve to deregulate APP gene expres-
sion, potentially contributing to AD pathogenesis (Fig-
ure 10). Aβ is a minority product of APP processing
[113]. Therefore, increase in APP levels could raise Aβ
above a risk threshold for AD. A theoretical union of
oncogenic and neurodegenerative models has been
proposed in the latent early-life associated regulation
(LEARn) model of idiopathic neuropsychiatric disor-
ders [38,39], expands and extends the “n-hit” model of
pathogenesis commonly accepted in oncology to
“sporadic” neurodegenerative disorders. Given that the
predicted PuF site may be structurally vulnerable to
GG oxidation, and thus subject to the LEARn model,
we conclude that our work suggests connections
between processes that lead to cancer etiology and
sporadic neurobiological disorders, both conceptually
(LEARn vs. n-hit) and mechanistically (PuF regulation
of APP vs. PuF regulation of metastasis).
Methods
Reagents and enzymes
Unless specifically noted otherwise, reagents were pur-
chased from Sigma-Aldrich (St. Louis, MO), and enzymes
were purchased from New England Biolabs (Ipswich, MA)
or Roche Life Science (Indianapolis, IN).
Cell culture
PC12 and NB cell lines were obtained from ATCC and
cultured as described previously [114]. The plates were
incubated in 5% CO2 in a 37°C incubator. Cell culture
reagents were purchased from Invitrogen/Life Technolo-
gies (Carlsbad, CA).
PRE fragments and oligomers
The rhesus monkey APP promoter clone pβXbB [17]
(Figure 11) was digested with restriction enzymes PvuII
and XhoI and run on a 10% TAE-polyacrylamide gel.
The cell type specific 30 nt (−76/−47) PRE [27] was
purified and end-labeled with γ
32P-ATP (Amersham,
Figure 11 Clone pβXbB. A deletion series of 6kb of the APP promoter and 50-UTR was previously constructed [17]. Within this series, an XbaI/
BamHI 408bp fragment of the APP proximal promoter and 50-UTR was inserted in the expression vector pBLCAT3 (Promega). This fragment
contained the PRE. The clone was used as the base template for all mutagenesis described herein.
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http://www.biomedcentral.com/1471-2164/14/68Piscataway, NJ) by T4 polynucleotide kinase (Roche,
I n d i a n a p o l i s ,I N ) .I na d d i t i o n ,o l i g o m e r sc o r r e s p o n d i n g
to this sequence and its reverse complement were
synthesized (Invitrogen) and similarly radiolabeled. The
oligomer pair differs from the plasmid fragment in that it
does not have a “TCGA” 5
0 overhang. This overhang was
filled for wildtype and mutant (see “Semiquantitative
EMSA of mutant PRE oligomers...”, herein) synthetic
double-stranded oligomers.
Analysis of potential transcription factor binding sites on
the PRE
The TESS [40] and MatInspector [41] utilities were used
to probe the TransFac database with the PRE sequence.
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Figure 12 PRE mutant designs. TESS predictions of transcription factor binding sites (Table 1) were used to design oligomers for deleting one
or more putative transcription factor binding sites in the PRE. A. Wildtype PRE sequence with all target sites indicated by rectangles
corresponding to TF positions. B-H. Mutant oligomers with specific target sites indicated by rectangles corresponding to TF positions. TF sites
introduced by mutagenesis have boldface and underlined names. Specific base mutations indicated by boldface and underline in sequences.
Lahiri et al. BMC Genomics 2013, 14:68 Page 20 of 28
http://www.biomedcentral.com/1471-2164/14/68EMSA of PRE fragments in human tissue nuclear extracts
Cell nuclei extracts from human brain, heart, liver, and
lungs were prepared as previously described [115,116].
The assay was carried out with 40 pg of PRE from diges-
tion of pβXbB (about 10,000 cpm) and 10 to 20 μgo f
nuclear extracts. Radioactive probe was incubated with
human brain, heart, liver, or lung nuclear extracts in
24μl of EMSA-binding buffer (Active Motif, Carlsbad
CA) at 6°–8°C for 40 minutes. The samples were mixed
with loading dye and the products of the reaction were
separated on a 5% nondenaturing polyacrylamide gel
electrophoresis (PAGE) in 1 x TGE (50 mM Tris, 384
mM glycine, and 2 mM EDTA). The gel was dried and
exposed to X-ray film for autoradiography. Free oligonu-
cleotides ran at the bottom of the gel. Protein-DNA
complexes were detected as mobility-retarded bands.
EMSA in nuclear extracts from normal and variously
stimulated PC12 and human U937 cells
Nuclear extracts were obtained commercially (Active-
Motif). PRE oligomer pairs were annealed and radiola-
beled as described herein. Radioactive oligomer pairs
were incubated with nuclear extracts from PC12, hyp-
oxic PC12, U937, and U937 stimulated with either IFN-
γ,T P A ,o rI F N - γ +T P A .I na d d i t i o n ,o n es a m p l ew a s
incubated with U937 nuclear extracts and 200x molar
excess of unlabeled PRE oligomer pairs. Reaction
mixtures were analyzed on nondenaturing PAGE and
the gel used for autoradiography.
Competition EMSA in nuclear extracts from NB and HeLa
cells
Cell nuclear extracts from NB and either HeLa cultures or
HeLa treated with TPA were obtained commercially (Ac-
tive Motif). Oligomer pairs for the PRE were annealed
and radiolabeled as described herein. Nuclear extracts and
oligomer pairs were incubated as described herein, except
that some individual samples were incubated with 200x
molar excess of unlabeled oligomer pairs. NB extracts
were either uncompeted or competed against unlabeled
PRE or commercially-obtained oligomer pairs (Santa Cruz
Biotechnology, Santa Cruz, CA) known to bind AP1, AP2,
SP1, or USF1. EMSA in unstimulated HeLa extracts was
not subject to competition. Extracts from TPA-stimulated
HeLa were either uncompeted or competed against un-
labeled PRE or commercially-obtained oligomers known
to bind AP1, AP2, or USF1. Reaction products were sepa-
rated on 5% nondenaturing PAGE and used for autoradi-
ography as described herein.
Antibody-supershift EMSA of the PRE in NB extracts vs.
several antisera
PRE oligomer pairs were annealed and radiolabeled as
described herein. Labeled oligomers were incubated with
Table 8 Oligomers for EMSA of PRE-derived mutants
Oligomer Forward (F) 5
0 to 3
0a Reverse (R) 5
0 to 3
0
PRE (WT) 5
0-TCGAGTGCCGAGCGGGGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACCCCGCTCGGCACTCGA-3
0
M1 5
0-TCGAGTGCCGAGCGGGGTGGTACCGATCAG-3
0 5
0-CTGATCGGTACCACCCCGCTCGGCACTCGA-3
0
M4 5
0-TCGAGTGCCGAGCGGGGTGGGCCTGTACAG-3
0 5
0-CTGTACAGGCCCACCCCGCTCGGCACTCGA-3
0
M2 5
0-TCGAGTGCCGAGCGCTGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACAGCGCTCGGCACTCGA-3
0
M3 5
0-TCGAGTCGCGAGCGGGGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACCCCGCTCGCGACTCGA-3
0
M4 5
0-TCCATGGCCGAGCGGGGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACCCCGCTCGGCCATGGA-3
0
M6 5
0-TCGAGTGCCGATCGGGGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACCCCGATCGGCACTCGA-3
0
M7 5
0-TCGAGTCCGGAGCGGGGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACCCCGCTCCGGACTCGA-3
0
aUnderlined bases have been mutated from wildtype PRE.
Table 9 Oligomers for site-directed mutagenesis of the pβXbB PRE/CAT fusion plasmid
Oligomer Forward (F) 5
0 to 3
0 Reverse (R) 5
0 to 3
0 RE
a
M1m-F 5
0-CCGAGCGGGGTGGTACCGATCAGCTGACTTGCC-3
0 5
0-GGCAAGTCAGCTGATCGGTACCACCCCGCTCGG-3
0 KpnI
M4m-F 5
0-CGAGCGGGGTGGGCCTGTACAGCTGACTTGCC-3
0 5
0-GGCAAGTCAGCTGTACAGGCCCACCCCGCTCG-3
0 BsrGI
M2m-F 5
0-TCGAGTGCCGAGCGCTGTGGGCCGGATCAG-3
0 5
0-CTGATCCGGCCCACAGCGCTCGGCACTCGA-3
0 AfeI
M3m-F 5
0-CTGGATCTCGAGTCGCGAGCGGGGTGGGC-3
0 5
0-GCCCACCCCGCTCGCGACTCGAGATCCAG-3
0 NruI
M4m-F 5
0-CCAGATCTGGATCTCCATGGCCGAGCGGGGTGGG-3
0 5
0-CCCACCCCGCTCGGCCATGGAGATCCAGATCTGG-3
0 NcoI
M6m-F 5
0-CTCGAGTGCCGATCGGGGTGGGCCG-3
0 5
0-CGGCCCACCCCGATCGGCACTCGAG-3
0 PvuI
M7m-F 5
0-CTGGATCTCGAGTCCGGAGCGGGGTGGGCCG-3
0 5
0-CGGCCCACCCCGCTCCGGACTCGAGATCCAG-3
0 BspEI
aRE: Restriction enzyme introduced.
bMutated oligonucleotides are underlined.
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without antiserum or separately with antiserum against
the nuclear factors AP1, AP2, SP1, PuF, USF1, or USF2
(Santa Cruz Biotechnology). In addition, one reaction was
incubated with both of the two antisera against AP2 and
PuF. Reactions were analyzed on nondenaturing 5% non-
denaturing PAGE and the gel subject to autoradiography.
Southwestern hybridization of the PRE vs. nuclear
extracts from NB, HeLa, TPA-stimulated HeLa, and PC12
cells
Nuclear extracts from NB, HeLa, TPA-stimulated HeLa,
and PC12 cells (5μg of each) were subject to denaturing
PAGE on a 10% gel containing 0.1% SDS. Proteins were
transferred to 0.2μm nitrocellulose membranes and
probed with radiolabeled PRE as we have previously
described [117]. Briefly, membranes were incubated over-
night at 4°C in renaturation buffer (10 mM HEPES pH
7.9, 50 mM NaCl, 0.1 mM EDTA 10 mM MgCl2, 10% gly-
cerol (v/v), 5% dry skim milk (w/v). Hybridization was
done in the same buffer reducing skim milk to 0.25% and
adding 10 μg poly-dI:dC and 10
6 CPM/ml radiolabeled
probe. Membranes were incubated with probe for 24
hours and washed twice in 50 ml of hybridization buffer
lacking poly-dI:dC and probe, 15 minutes per wash, fol-
lowed by autoradiography.
Mutagenic studies of the PRE sequence, design of PRE
mutants
The PRE sequence was used as a template to design
mutants for selected predicted transcription factor
binding sites (Figure 12). Two sets of complementary
oligomer pairs were synthesized (Invitrogen) according
to these designs. The first set consisted of oligomers
that were mutated versions of the PRE for EMSA stud-
ies (Table 8). The second set consisted of oligomers for
generating site-directed mutant CAT fusion clones
(Table 9), based on the pβXbB [17] APP-CAT fusion
clone. This parent vector contains a 408nt proximal
fragment of the APP gene promoter and 5
0-UTR (Fig-
ure 12). The TransFac database was probed with TESS
[40] and MatInspector [41] to determine specific
changes in potential TF binding sites. Each mutant
deleted specific predicted TF binding sites and inciden-
tally created other TF sites (Table 10).
Semiquantitative EMSA of mutant PRE oligomers with NB
and PC12 extracts
Oligomer pairs of wildtype PRE and 7 mutants (Table 8)
were commercially obtained (Invitrogen), annealed, and
radiolabeled. The labeled double-stranded oligomers
were used in EMSA reactions with NB and PC12 nu-
clear extracts, as described herein. Gels were used for
autoradiography. The autoradiographs were densitomet-
rically scanned and the scans quantified with ImageJ
analysis software [118]. Both band density and position
were measured. Dunnett’s two-tailed t test was used to
analyze both density and migration differences of each
mutant compared to wildtype PRE.
Mutagenesis of the PRE sequence in the pβXbB CAT
reporter clone
Mutagenic oligomers (Table 9) were designed and
synthesized (Invitrogen). These oligomers were used
with the QuikChange site-directed mutagenesis kit (Stra-
tagene, CA) to insert specific mutations into the PRE se-
quence within the APP promoter/CAT reporter fusion
clone pβXbB (Figure 12). Mutants were initially screened
by digestion with designed restriction enzyme sites
(Table 9) and confirmed via DNA sequencing (Macrogen
Korea, Seoul, South Korea).
Table 10 Mutations induced in the PRE
Variant Sites deleted Sites created
Wildtype PRE
M1 AP2, GATA1, GC Box (II)
a,
PuF, R, SP1 (I)
b
AML1a
M2 AP2, GC Box (I), GATA1,
Pax4α, PuF, SP1 (I)
AML1a/AML1c, AP4,
GT-IIBα
M3 R, TCERG (I)
c
M4 GATA1/GATA2, SP1 (II) GR, PR
M5 R, TCERG (I) YY1
M6 TCERG1 (II) GATA1/GATA2
M7 TCERG1 (I, II), R
aTwo distinct GC boxes were identified in the wildtype PRE sequence and are
designated as “I” and “II”.
bTwo distinct SP1 sites in addition to the GC boxes were identified in the
wildtype PRE sequence and are designated as “I” and “II”.
cTwo distinct TCERG1 sites were identified in the wildtype PRE sequence and
are designated as “I” and “II”.
Table 11 Symbols in effect size equations
Symbol Use
g unbiased standard difference
GM grand mean of experiment
k total groups of test
mc mean value of PRE wildtype control
mj mean value of group j
MSerror mean square error of ANOVA
n replicates within each group
Γ() gamma function
Ψ root mean square standard effect
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Cells were transfected with wildtype and mutated CAT
reporter constructs by the Lipofectamine plus kit (Invi-
trogen). Briefly, transfection was carried out with 2.7 μg
of DNA of each CAT-reporter plasmid. To monitor
transfection efficiency, cells were cotransfected with 0.3
μgp S V βGAL (Promega). Following DNA transfections,
cells were harvested, cell extracts prepared, and protein
concentration determined by Bradford assay (BioRad,
Hercules, CA).
Table 12 Sequences for interspecies PRE sequence comparison
Species Abbreviation Common name Sequence Loc.
a Base
weight
b
Homo sapiens Hom sap human [GenBank:NT_011512.1] 13204753..13205282 11
Pan troglodytes Pan tro chimpanzee [GenBank:NT_106996.1] 12354873..12355401 11
Gorilla gorilla Gor gor western gorilla Ensembl:gorGor3.1:21 14453005..14453533 10
Pongo pygmaeus Pon pyg Bornean orangutan [GenBank:NW_002891078.1] 100309..100838 10
Nomascus leucogenys Nom leu northern white-cheeked
gibbon
[Genbank:NW_003501402] 11777748..11778275 7
Macaca mulatta Mac mul rhesus monkey [GenBank:NW_001114168.1] 7908454..7908980 7
Callithrix jacchus Cal jac common marmoset [GenBank:NW_003184659] 4142710..4143249 6
Tarsius syrichta Tar syr Philippine tarsier [GenBank:ABRT010367312] 35..605 5
Otolemur garnettii Oto gar greater galago Ensembl:scaffold:OtoGar3:
GL873528.1
10760940..10765774 4
Cavia porcellus Cav por guinea pig [GenBank:NT_176367] 7334345..7334880 10
Octodon degus Oct deg common degu [GenBank:AJSA01048215] 19979..20497 10
Heterocephalus glaber Het gla naked mole rat [GenBank:AFSB01163805] 427..1000 6
Ictidomys
tridecemlineatus
Ict tri thirteen-lined ground squirrel [GenBank:AAQQ01741479] 107..624 9
Mus musculus Mus mus house mouse [GenBank:NT_039625.8] 19878914..19879574 9
Rattus norvegicus Rat nor Norway rat [GenBank:NW_047354] 24693771..24694300 8
Dipodomys ordii Dip ord Ord’s kangaroo rat [GenBank:ABRO01075802] 1..581 6
Oryctolagus cuniculus Ory cun European rabbit [GenBank:NW_003159292] 59870509..59871025 5
Ochotona princeps Och pri American pika [GenBank:AAYZ01049311] 693..1006 5
Bos primigenius taurus Bos pri t cow [GenBank:NW_003103795.1] 2852543..2853063 12
Bos primigenius indicus Bos pri i zebu [GenBank:AGFL01000631] 71936..72456 12
Tursiops truncatus Tur tru bottlenose dolphin [GenBank:ABRN02546477] 189..717 7
Sus scrofa Sus scr pig [GenBank:NW_003611878] 681338..681875 6
Ailuropoda melanoleuca Ail mel giant panda [GenBank:NW_003217675] 561990..562540 8
Mustela puturius furo Mus put f domestic ferret [GenBank:AEYP01042946] 556..1076 8
Canis lupus familiaris Can lup f dog [GenBank:NW_003726114] 21614163..21614717 7
Pteropus vampyrus Pte vam flying fox [GenBank:ABRP01159960] 503..1000 4
Condylura cristata Con cry star-nosed mole [GenBank:AJFV01010076] 10886..11380 3
Loxodonta africanus Lox afr African elephant [GenBank:NW_003573433.1] 30067875..30068350 4
Procavia capensis Pro cap rock hyrax [GenBank:ABRQ01094447] 1072..1437 4
Echinops telfairi Ech tel lesser hedgehog tenrec [GenBank:AAIY01071949] 2252..2666 3
Choloepus hoffmanni Cho hof Hoffman’s two-toed sloth [GenBank:ABVD01435293] 1..364 3
Dasypus novemcinctus Das nov nine-banded armadillo [GenBank:AAGV03159065] 1..297 3
Macropus eugenii Mac eug Tammar wallaby [GenBank:ABQO020034033] 684..1293 2
Sarcophilus harrisii Sar har Tasmanian devil [GenBank:AEFK01137980] 744..1216 2
Mondelphis domestica Mon dom gray short-tailed opossum [GenBank:NW_001581956.1] 6492289..6491655 1
aLocation within accession numbered database sequence.
bBase weight was used to determine specific weights for each analysis as described in the main text.
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clones by ELISA
Reporter CAT protein levels in cells transfected by wild-
type and each mutated clone were measured with an
ELISA kit (Roche, Indianapolis), and CAT protein levels
were adjusted to total protein content of extracts. Each
assay was performed as described previously [114].
Results from adjusted reporter gene activity were statisti-
cally analyzed via Dunnett’s multiple t.
EMSA of selected PRE mutants in nuclear extracts from
different cell lines and from cell lines subjected to
hypoxia, serum starvation, or induction with different
cytokines
Nuclear extracts from HeLa; HeLa cultured with TPA;
NB; NIH3T3; NIH3T3 cultured under serum starvation
(SR), IL6, or TGFβ; PC12; PC12 cultured under hypoxia;
U373 cell lines; human brain; or mouse brain were
obtained commercially (ActiveMotif) or prepared as pre-
viously described [119]. Oligomer pairs for the PRE and
for mutants M1, M4, and M6 (Table 8) were annealed
and radiolabeled and oligomers and extracts were incu-
bated, electrophoresed on 5% native TGE-PAGE, and
gels used for autoradiography as described herein.
Statistical analysis
All statistical analysis was done with the R statistical lan-
guage [120]. Data were checked by Anderson-Darling
test for normality of residuals and non-linearly trans-
formed if necessary. Each mutant’s mean adjusted signal
was compared to wildtype by Dunnett’s multiple t [121],
p ≤ 0.05. Root mean square standardized effect [122]
with sample size bias adjustment was calculated for each
assay with the equation , and unbiased standardized
pairwise mean differences (g) between wildtype PRE and
each mutant within each assay were also calculated with
the equation g ¼
mj mc ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MSerror
p  
Γ 2n 2
2 ðÞ
Γ 2n 3
2 ðÞ
ﬃﬃﬃﬃﬃﬃ
2n 2
2
p [43]. Symbols in
these equations are explained in Table 11. The Ψ stan-
dardized effect size has a comparable range to g, since Ψ
expresses effect size in
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MSerror
p
of the ANOVA, which
is analogous to standard deviation of a single pairwise
comparison.
Interspecies analysis of the PRE
Genomic sequences identified or preliminarily identified
as proximal promoter elements of the APP genes of 35
mammal species (Table 12) were downloaded from
NCBI/GenBank. Sequences were aligned by WebPrank
[44], and the alignment was trimmed at each end. The
resulting alignment covered −326/+202 in the human se-
quence. Taxonomically weighted mean information con-
tent was calculated for a 100 nt window, along with 95%
confidence intervals, in the alignment, ignoring any re-
gion that was a gap within the primates. In addition, the
portion of the alignment corresponding to the PRE se-
quence was used to calculate taxonomically weighted
homologies and sequence logos [45]. “Base weights”
were assigned on the basis of each clade equally as it
joined to the taxonomic guide tree as a whole. These
“base weights” were then converted by the equation
2
1
baseweight into “working weights”. Information content was
then multiplied by individual working weights before
combination with other taxons. The working weights
were also adjusted within each analysis so that the
highest-value working weight was equal to 1. This
process was meant to partially compensate for “over-
representation” of some phylogenic groups vs. others in
the analyses.
In addition, maximum likelihood distances for the
complete edge-trimmed alignment were generated by
TreePuzzle [123]. Gaps were encoded as suggested by
Felsenstein [124] and DNAPARS was used to create an
input tree, which was used with the distance matrix to
estimate phylogeny with FITCH. The tree was artificially
rooted between marsupials and eutheria. Root-to-tip dis-
tances were calculated for each species and compared to
mean root-to-tip distance ± 95% confidence interval,
Bonferroni-adjusted for 35 comparisons.
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